Welcome to our dedicated page for APOLLOMICS SEC filings (Ticker: APLM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Apollomics Inc. filings document the regulatory record of a foreign private issuer developing oncology therapies. Its Form 6-K reports furnish financial-results releases, clinical-development updates for vebreltinib (APL-101), material agreements and license matters, related-party convertible-note financing, collaboration updates, and operational-continuity disclosures.
The filing record also covers governance and control procedures, including director appointments and committee composition, auditor changes, registration-statement incorporation, and litigation-related disclosures. These filings place Apollomics' oncology pipeline, capital structure, public-company governance and risk matters into formal SEC-reporting categories.
Apollomics Inc. provided an operational continuity update, reversing prior plans to wind up after receiving $4.1 million in PIPE funding and appointing a new board and management team. The company will continue its global Phase 2 SPARTA trial of APL-101 (vebreltinib), a targeted therapy with positive results across more than 280 patients.
Management notified CROs and licensing partners of the transition and continuation of trials; contracts with current CROs are fully paid and up to date. Apollomics aims to support regulatory submissions in the U.S., EU and other markets, and plans to leverage Chinese approvals for MET-amplified NSCLC and GBM via its partner to pursue submissions in Southeast Asia, the Middle East and other regions. The company has 12 full-time employees and expects headcount to reach 15 by October 31, 2025, with a planned shift of roles from China to the U.S. and Taiwan.
Apollomics Inc. (APLM) disclosed two press-release exhibits: one announcing receipt of a Nasdaq delisting determination letter and a second stating the company has completed filing an appeal of the Nasdaq delisting order. The filings are attached as Exhibits 99.1 and 99.2. The current report is dated September 25, 2025 and is signed by Peter Lin, Chief Financial Officer. The document does not include financial results, specific reasons for the delisting determination, timelines for the appeal process, or details about potential remedies.